Cisplatin and other platinum-based chemotherapeutic drugs have been used extensively for
the treatment of human cancers such as bladder, blood, breast, cervical, esophageal, head …

Cancers arising from the esophagus, including the gastroesophageal junction, are relatively
uncommon in the United States—the lifetime risk of this cancer is 0.8 percent for men and …

Cancers originating in the esophagus or esophagogastric junction constitute a major global
health problem. Esophageal cancers are histologically classified as squamous cell …

Gastric cancer is the third leading cause of cancer-related deaths worldwide. Over 95% of
gastric cancers are adenocarcinomas, which are typically classified based on anatomic …

Esophageal cancer is the sixth leading cause of cancer-related deaths worldwide.
Squamous cell carcinoma is the most common histology in Eastern Europe and Asia, and …

Esophageal cancer is the sixth most common cause of cancer deaths worldwide.
Adenocarcinoma is more common in North America and Western European countries …

In this multicenter, single-arm phase 2 trial (ChiCTR1900024428), patients with locally
advanced gastric/gastroesophageal junction cancers receive one cycle of sintilimab (anti …

There is a need for new, safer, and more effective agents to treat cancer. Cytostatics that
have transition metals at their core have attracted renewed interest from scientists …

Purpose To identify baseline prognostic factors and assess whether pretreatment quality of
life (QoL) predicts survival in patients with locally advanced or metastatic esophago-gastric …

BACKGROUND In patients with locoregional carcinoma of the esophagus or
esophagogastric junction who underwent preoperative chemoradiation, it is unclear whether …